Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: LoLoLoLita who wrote (3911)	12/19/1997 1:06:00 PM
From: Zebra 365	Read Replies (3) \| Respond to of 23519

Two brand names of Yohimbine are available, Yohimex and Yocon. This is the product info on Yocon: DESCRIPTION: Yohimbine is a 3alpha-15alpha-20beta-17alpha- hydroxy-Yohimbine-16alpha-carboxylic acid methyl ester. The alkaloid is found in Rubaceae and related trees. Also in Rauwolfia Serpentina (L) Benth. Yohimbine is an indolalkylamine alkaloid with chemical similarity to reserpine. It is a crystalline powder, odorless. Each compressed tablet contains (1/12 gr.) 5.4 mg of Yohimbine Hydrochloride. ACTIONS/CLINICAL PHARMACOLOGY: Yohimbine blocks presynaptic alpha-2 adrenergic receptors. Its actions on peripheral blood vessels resembles that of reserpine, though it is weaker and of short duration. Yohimbine's peripheral autonomic nervous system effect is to increase parasympathetic (cholinergic) and decrease sympathetic (adrenergic) activity. It is to be noted that in male sexual performance, erection is linked to cholinergic activity and to alpha-2 adrenergic blockade which may theoretically result in increased penile inflow, decreased penile outflow or both. Yohimbine exerts a stimulating action on the mood and may increase anxiety. Such actions have not been adequately studied or related to dosage although they appear to require high doses of the drug. Yohimbine has a mild anti-diuretic action, probably via stimulation of hypothalamic centers and release of posterior pituitary hormone. Reportedly, Yohimbine exerts no significant influence on cardiac stimulation and other effects mediated by beta-adrenergic receptors, its effect on blood pressure, if any, would be to lower it; however, no adequate studies are at hand to quantitate this effect in terms of Yohimbine dosage. INDICATIONS AND USAGE: YOCON is indicated as a sympathicolytic and mydriatic. It may have activity as an aphrodisiac. CONTRAINDICATIONS: Renal diseases, and patients sensitive to the drug. In view of the limited and inadequate information at hand, no precise tabulation can be offered of additional contraindications. WARNINGS: Generally, this drug is not proposed for use in females and certainly must not be used during pregnancy. Neither is this drug proposed for use in pediatric, geriatric or cardio-renal patients with gastric or duodenal ulcer history. Nor should it be used in conjunction with mood- modifying drugs such as antidepressants, or in psychiatric patients in general. DRUG INTERACTIONS: SEE WARNINGS ADVERSE REACTIONS: Yohimbine readily penetrates the (CNS) and produces a complex pattern of responses in lower doses than required to produce peripheral alpha- adrenergic blockade. These include anti-diuresis, a general picture of central excitation including elevation of blood pressure and heart rate increased motor activity, irritability and tremor. Sweating, nausea and vomiting are common after parenteral administration of the drug. (REF. 1,2) Also dizziness, headache, skin flushing reported when used orally. (REF. 1,3) DOSAGE AND ADMINISTRATION: Experimental dosage reported in treatment of erectile impotence: (REF. 1,3,4,) 1 tablet (5.4 mg) 3 times a day, to adult males taken orally. Occasional side effects reported with this dosage are nausea, dizziness or nervousness. In the event of side effects dosage is to be reduced to 1/2 tablet 3 times a day, followed by gradual increases to 1 tablet 3 times a day. Reported therapy not more than 10 weeks. (REF. 3) HOW SUPPLIED: Oral tablets of Yocon(R) 1/12 gr 5.4 mg in bottles of 100's NDC 53159-001-01, 1000's NDC 53159-001-10, and blister-paks of 30's NDC 53159-001-30. Rev. January 1985 REFERENCES: 1. A. Morales et al., New England Journal of Medicine:1221. November 12, 1981. 2. Goodman, Gilman--The Pharmacological Basis of Therapeutics 6th ed., p. 176-188, McMillan 3. Weekly Urological Clinical letter, 27:2, July 4, 1983. 4. A. Morales et al., The Journal of Urology 128: 45-47, 1982.